

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/64		A1	(11) International Publication Number: WO 95/09184 (43) International Publication Date: 6 April 1995 (06.04.95)
(21) International Application Number: PCT/US94/10867		(81) Designated States: AM, AU, BG, BR, BY, CA, CN, CZ, EE, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MN, NZ, PL, RO, RU, SI, SK, TJ, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 26 September 1994 (26.09.94)		Published <i>With international search report.</i>	
(30) Priority Data: 08/128,912 29 September 1993 (29.09.93) US			
(71)(72) Applicants and Inventors: SEED, Brian [US/US]; 9 Hawthorne Place #5J, Boston, MA 02114 (US). SEED, John, C. [US/US]; 205 Witherspoon Street, Princeton, NJ 08540 (US).			
(74) Agent: LECH, Karen, F.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110 (US).			

(54) Title: USE OF RELAXIN AS AN ANALGESIC AND PALLIATIVE FOR INTRACTABLE PAIN

(57) Abstract

Disclosed is the use of relaxin in the manufacture of a medicament for the treatment of pain. Also disclosed is a method of reducing pain in a mammal involving administration of relaxin to the mammal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

Use of Relaxin as an Analgesic and
Palliative for Intractable Pain

Background of the Invention

5 This invention relates to the use of relaxin to reduce pain.

Relaxin is a peptide hormone primarily synthesized by the theca interna cells of the corpus luteum during pregnancy. It may also be synthesized in small amounts 10 by the human uterus and placenta. It is known to cause relaxation of the pubic symphysis prior to parturition.

Summary of the Invention

In general, the invention features a method of reducing pain in a mammal which involves administering 15 relaxin to the mammal. In preferred embodiments, the mammal is a human; the pain is chronic; and the pain results from stretching, swelling, or dislocation of a tissue of the mammal (for example, chronic back pain, tumor pain, iatrogenic pain, arthritic joint pain, or 20 postpartum pelvic joint pain).

The invention also features the use of relaxin in the manufacture of a medicament for the treatment of pain. In preferred embodiments, the pain is chronic; and the pain results from stretching, swelling, or 25 dislocation of a tissue of the mammal (for example, chronic back pain, tumor pain, iatrogenic pain, arthritic joint pain, or postpartum pelvic joint pain).

Other features of the invention will be apparent from the following description of the preferred 30 embodiments thereof, and from the claims.

- 2 -

Description of the Preferred Embodiments

Although relaxin may be used generally as an analgesic and palliative for pain, the conditions most amenable to its therapeutic administration are those in which unusual stress is chronically placed on tissues because of an acquired or inherent malformation which results in the displacement of tissues from their natural disposition in the body. Relaxin finds utility, for example, in the treatment of severe chronic pain, particularly pain arising from stretching, swelling, or dislocation of tissues. A partial list of preferred therapeutic indications follows; this list is provided to illustrate, not limit, the invention.

Chronic back pain

Chronic back pain is generally due to one or more of the following six causes: (i) stress on intervertebral facet joints, caused by slippage, arthritis, wedging, or scoliosis; (ii) radiculopathy, the mechanical compression of the nerve root due to bulging discs or tumors; (iii) tendonitis or tendon sprain; (iv) muscle spasm or muscle sprain; (v) ischemia, a local insufficiency in circulatory flow; and (vi) neuropathy, damage to nervous tissue of metabolic etiology or arising from cord tumors or central nervous system disease. The first four of these causes of chronic back pain account for the great majority of cases, all of which are amenable to relaxin therapy.

Tumor Pain

The local unrestricted proliferation of cells in cancer leads to pain when the displaced tissues are subjected to the mechanical stress required to accommodate the increased volume occupied by the tumor mass. This pain has as its underlying cause the severe local stretching of tissues by the neoplastic lesion. When the tumor burden is confined to a small enclosed

- 3 -

compartment, such as the marrow of a bone, the resulting pressure can result in severe pain which can be very difficult to manage clinically. Use of relaxin in the management of tumor pain will prove a valuable adjunct to 5 more conventional, opioid-based therapies.

Iatrogenic Pain

Following invasive procedures or high dose radiation therapy, it is not uncommon for scar tissue to form which results in a debilitating compromise of 10 freedom of motion and substantial chronic pain.

Treatment with relaxin will reduce pain while also promoting the loosening of connective tissue structures.

Arthritic Joint Pain

The pain associated with osteoarthritis and 15 rheumatoid arthritis appears to arise from local inflammation and the associated stimulation of nociceptive neurons. Administration of relaxin will substantially decrease the perception of painful stimuli in these conditions.

20 Postpartum Pelvic Joint Pain

In a small fraction of women, parturition precipitates chronic pain in the pelvis and pelvic joints. A correlation has been observed between women with high relaxin levels during pregnancy and the 25 subsequent development of postpartum pelvic pain. Although the etiology of this pain is not understood, it is likely that it arises from a chronic intrapelvic tension similar to that found in lower back pain, and a return to the high relaxin levels experienced during 30 pregnancy will palliate the symptomology.

Therapy

Systemic Administration of Relaxin

For use as a pain reducer, relaxin may be administered systemically, for example, formulated in a

- 4 -

pharmaceutically-acceptable buffer such as physiological saline. Preferable routes of administration include, for example, subcutaneous, intramuscular, or intradermal injections which provide continuous, sustained levels of
5 the drug in the patient. In other preferred routes of administration, relaxin may be given to a patient by injection of a slow release preparation, slowly dissociating polymeric form, or crystalline form; this sort of sustained administration may follow an initial
10 delivery of the drug by more conventional routes (for example, those described above). Alternatively, relaxin may be administered using an infusion pump, thus allowing a precise degree of control over the rate of drug release, or through instillation of relaxin in the nasal
15 passages in a similar fashion to that used to promote absorption of insulin. Finally, as an alternative to nasal transmucosal absorption, relaxin may be delivered by aerosol deposition of a powder or solution into the lungs.
20

20 Local Administration of Relaxin

Relaxin may also be administered locally to achieve substantial palliative outcomes. Since the desired action of the agent is generally upon a circumscribed mass of tissue proximate to a specific
25 stress, delivery of the hormone by means which promote high local concentrations in the vicinity of the stress may be especially desirable. For this reason injection of the agent into tissue sites adjacent to, or upstream of the draining circulation of the affected site will,
30 where possible, be preferable. Alternatively, in conditions involving deep organ structures, for example in the displacement of tissue by invasive tumors, implantation near the affected site of sustained release formulations of relaxin (such as osmotic pumps or

- 5 -

erodable polymeric compositions impregnated with the hormone) may be preferred.

Relaxin

Relaxin, for either systemic or local administration, may be obtained from any commercially available source (e.g., Genentech, Inc., South San Francisco, CA) or may be synthesized either by standard techniques of recombinant polypeptide production (see, e.g., Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1989; Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989) or by peptide synthesis (e.g., by the methods described in *Solid Phase Peptide Synthesis*, 2nd ed., 1984 The Pierce Chemical Co., Rockford, IL). Relaxin gene and peptide sequences are provided, e.g., in Hudson et al., *Nature* 301:628, 1983; Hudson et al., *EMBO J.* 3:2333, 1984; and Bryant-Greenwood, *Molecular and Cellular Endocrinology* 79:C125, 1991.

Generally, the relaxin polypeptide native to a species will be preferred for therapeutic administration. However, relaxin fragments or analogs shown to be functional, e.g., in the bioassays of Fei et al. (*Biochem. Biophys. Res. Comm.* 170:214-222, 1990) and Kramer et al. (*In Vitro Cell. Dev. Biol.* 26:647-656, 1990) are also useful in the invention. Particularly preferred relaxin fragments include the B29 relaxin fragment described by Winslow et al. (*Proc. 71st Meeting of Endocrine Society* 889 Abstract, 1989) and Bryant-Greenwood (*supra*). Particularly preferred relaxin analogs include polypeptides which differ from a native relaxin polypeptide only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, aspartic acid for glutamic

- 6 -

acid, etc.). Other preferred analogs include relaxin polypeptides which are modified for the purpose of increasing peptide stability; such analogs may contain, e.g., one or more desaturated peptide bonds or D-amino acids in the peptide sequence or may be formulated as cyclized peptide molecules. Finally, a prorelaxin polypeptide (see, e.g., Hudson et al., EMBO J. 3:2333, 1984; and Vu et al., Life Sci. 52:1055, 1993) may be administered as an analgesic and palliative for pain according to the invention.

Dosage

Relaxin is administered systemically at a dosage that provides reduction in pain, typically between 0.1-1.6 nanogram/ml and preferably 0.7 nanogram/ml. Where local administration schemes are employed, the concentrations of relaxin in the affected tissue may substantially exceed these levels.

Because administration of the relaxin polypeptide may promote loosening of connective tissues, it may be desirable, where possible, to encourage muscular development through physical therapy to counteract any excessive loosening observed during the course of relaxin treatment.

Other Embodiments

The methods of the invention may be used to reduce the disorders described herein in any mammal, for example, humans, domestic pets, or livestock. Where a non-human mammal is treated, the relaxin employed is preferably specific for that species (see, e.g., Haley et al., DNA 1:155, 1982).

Other embodiments are within the following claims.

- 7 -

Claims

1. A method of reducing pain in a mammal, comprising administering relaxin to said mammal.
2. The method of claim 1, wherein said pain is
5 chronic.
3. The method of claim 1, wherein said pain results from stretching, swelling, or dislocation of a tissue of said mammal.
4. The method of claim 1, wherein said pain is
10 chronic back pain.
5. The method of claim 1, wherein said pain is tumor pain.
6. The method of claim 1, wherein said pain is iatrogenic pain.
- 15 7. The method of claim 1, wherein said pain is arthritic joint pain.
8. The method of claim 1, wherein said pain is postpartum pelvic joint pain.
9. Use of relaxin in the manufacture of a
20 medicament for the treatment of pain.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/10867

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 14/64

US CL : 514/12; 530/324

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12; 530/324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,656,249 (TREGEAR) 07 April 1987, see entire document.	1-9
X	US, A, 5,145,962 (HUDSON) 08 September 1992, see entire document.	1-9
X	US, A, 5,179,195 (HUDSON) 12 January 1993, see entire document.	1-9

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 20 NOVEMBER 1994	Date of mailing of the international search report 12 DEC 1994
---	---

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer P. LYNN TOUZEAU, PH.D. Telephone No. (703) 308-0196
---	--

Form PCT/ISA/210 (second sheet)(July 1992)★